EBQ:Sgarbossa Criteria Study: Difference between revisions
No edit summary |
No edit summary |
||
| Line 48: | Line 48: | ||
===Primary Outcome=== | ===Primary Outcome=== | ||
[[Acute Myocardial Infarction]] | [[Acute Myocardial Infarction]] | ||
==Criticisms & Further Discussion== | ==Criticisms & Further Discussion== | ||
Revision as of 21:22, 22 April 2014
Under Review Journal Club Article
Sgarbossa E. et al.. "Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators". NEJM. 1996. 334(8):481-7.
PubMed Full text PDF
PubMed Full text PDF
Clinical Question
How can we diagnose Acute Myocardial Infarction in patients with a Left Bundle Branch Block?
Conclusion
Sgarbossa's Criteria is a validated clinical prediction rule based on ECG criteria to diagnose Acute Myocardial Infarction in patients with a Left Bundle Branch Block. It has good specificity, but poor sensitivity.
Major Points
The Sgarbossa Criteria:
- ST-segment Elevation of at least 1 mm with concordance with the QRS complex with a score of 5
- ST-segment depression in leads V1, V2 or V3 with a score of 3
- ST-segment Elevation of atleast 5 mm with discordance with the QRS complex with a score of 2
With a score >3 90% of those with positive criteria will have STEMI (Good Specificity) But with negative criteria it doesn't help that much (Low sensitivity)
Population
Patient Demographics
- Median Age: 68 years
- Males: 64% in study group and 60% in experimental group
- Left Axis Deviation: 28% Vs. 48%
- Previous MI: 26% Vs. 59%
Inclusion Criteria
- Experiment: Patients with LBBB and Acute myocardial infarction (GUSTO-1 trial population)[1]
- Control: Patients with normal documented angiography with LBBB Randomly selected from Duke data bank for cardiovascular disease[2]
Exclusion Criteria
Patients without LBBB
Outcomes
Primary Outcome
Criticisms & Further Discussion
Funding
Grant from Bayer, Genentech, CIBA–Corning, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.
